Metastatic Cancer Clinical Trials in Rochester, Minnesota

5 studies are recruiting for metastatic cancer in Rochester, Minnesota right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. PRE-ISPY Phase I/II Oncology Platform Program

   PRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed to evaluate single agents or combinations in locally advanced, incurable, or metastatic solid tumors and/or oligometastatic malignancy and/…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota

   Locations

   10 in total

   Run by

   QuantumLeap Healthcare Collaborative

   See if you can join NCT05868226 on ClinicalTrials.gov

2. FOG-001 in Locally Advanced or Metastatic Solid Tumors

   The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic, Rochester, Minnesota

   Locations

   33 in total

   Run by

   Parabilis Medicines, Inc.

   See if you can join NCT05919264 on ClinicalTrials.gov

3. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

   This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic (Minnesota), Rochester, Minnesota

   Locations

   82 in total

   Run by

   Artios Pharma Ltd

   See if you can join NCT04657068 on ClinicalTrials.gov

4. (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

   This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 482 patients. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of CGT9486 to be used in subsequent …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Mayo Clinic, Rochester, Minnesota

   Locations

   126 in total

   Run by

   Cogent Biosciences, Inc.

   See if you can join NCT05208047 on ClinicalTrials.gov

5. Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

   Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic, Rochester, Minnesota

   Locations

   11 in total

   Run by

   Qurient Co., Ltd.

   See if you can join NCT05394103 on ClinicalTrials.gov